Loading...
•
Mar 31, 2023
Zentalis Q1 2023 Earnings Report
Reported first quarter 2023 financial results and provided operational updates.
Key Takeaways
Zentalis Pharmaceuticals reported a cash balance of $392 million as of March 31, 2023, with a projected cash runway into the second quarter of 2025. The company is on track to disclose monotherapy dose and updates on accruing trials for azenosertib in 1H 2023 and will present positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer at ASCO.
On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib in 1H 2023.
Positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer to be presented at the 2023 ASCO Annual Meeting.
Announced collaborations with Foundation Medicine and Roche Diagnostics to advance the development of azenosertib.
Appointed Diana Hausman, M.D. to Board of Directors and Funda Meric-Bernstam, M.D. to Scientific Advisory Board.
Forward Guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of March 31, 2023 will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...